Targeted pill tested for Tough-to-Treat bladder tumors
NCT ID NCT02657486
Summary
This small pilot study tested whether an oral drug called BGJ398 could shrink tumors in patients with a specific type of recurrent bladder cancer. It involved 4 adults whose cancer had returned after standard treatment and who had a particular genetic mutation. The goal was to see if the drug could eliminate visible tumors in the bladder lining.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.